Drug intelligence / Profile preview

AS-403

Development stage: Preclinical
Lead developer: Amyloid Solution
Modality: Small Molecules

Overview

AS-403 is a small molecule drug candidate currently in the lead optimization stage of preclinical development for the treatment of Alzheimer's disease. Developed by Amyloid Solution, it is part of the company's GLIA program, which focuses on modulating glial cell activity to address neurodegeneration and neuroinflammation. While the specific biological target of AS-403 remains non-disclosed, the program aims to provide therapeutic benefits by targeting glial-mediated pathways involved in the progression of Alzheimer's disease.

Beyond the preview

Go deeper on AS-403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AS-403.

Explore the full profile